Juniper Pharma Services strengthens capsule capability with Xcelodose

Xcelodose enables Juniper Pharma Services to accurately fill API directly into capsules

The move by the contract development and manufacturing organisation (CDMO) follows demand from its clients to develop the technique to complement its development services and help get new molecules to Phase I clinical trials quicker.

Xcelodose enables Juniper Pharma Services to accurately fill API directly into capsules in an efficient and automated manner to primarily support first-in-human studies, reduce formulation requirements and minimise drug substance wastage.

Claire Madden-Smith, senior VP at Juniper Pharma Services, said: “We have focused on having a broad range of development capabilities to enable our clients to rapidly access the most appropriate solution to meet their need. The increased usage of Xcelodose is a natural expansion of our manufacturing services.

“Encouragingly, the service is already helping satisfy the growing needs of our clients to get to clinical trials as quickly as possible without compromising on quality. The technique simply allows us to make and supply batches of the drug in capsules for clinic in a much more precise and economical manner.

“Given the shortage of CDMOs in the industry with the capability and expertise to offer Xcelodose in conjunction with associated development and analytical services, we expect a continuation of uptake of our enhanced offering.”

Xcelodose provides the automated processing of API directly into capsules at very low doses and is an ideal tool for highly soluble products and potent molecules. The use of the system removes the requirement for complex formulation development and allows companies to generate invaluable data on a compound in a cost effective way.

With an established track record of helping pharmaceutical companies and emerging biotechs develop new products and platforms, Juniper Pharma Services is able to optimise formulation performance through its science-led approach to projects.

The company has well-established GMP clinical manufacturing capabilities covering topical and oral dosage form products, including the supply of potent compounds and controlled drugs. Since 1997, the CDMO has built a strong reputation in materials characterisation, formulation analysis and IP consultancy.